LAKEFRONT BIOTHERAPEUTIC-ADR
LKFTNASDAQπ #1773 by market capUS Equity
ββ
Quote unavailableTrack LKFT
Get earnings, price moves & breaking news on Telegram
24hβ
7dβ
14dβ
30dβ
ytdβ
1yβ
π¦Market Cap
$2.18B
Small Cap
πRevenue Growth (YoY)
303.5%
High Growth
πGross Margin
98.0%
High
π΅FCF Margin
-28.9%
Thin
βοΈP/S Ratio
1.9x
Cheap
Otter Score
80
Strong
No chart data available for LKFT.
Trading Snapshot
- Day Range
- β
- 52-Week Range
- $25.68 β $36.24
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 65.5M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $1.11B
- Last Q Revenue
- $12M
- P/E Ratio
- 4.1
- P/S Ratio
- 1.9x
- EPS (TTM)
- $7.42
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +220749.3%
LAKEFRONT BIOTHERAPEUTIC-ADR
LKFTFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.1Bβ² +303.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
97.3%β² +11.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
$501MβΌ β366.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
65.9Mβ² +220749.3% YoY
About LAKEFRONT BIOTHERAPEUTIC-ADR
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
β‘Momentumβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Strong
80/100
Analyst data unavailable.
Latest News & Updates
News unavailable.